Media Requests
Please send all media-related inquiries and interview requests to mediarelations@lls.org.
An LLS representative will respond as soon as possible.
Burlington Stores & its Customers Raise Nearly $4 Million for The Leukemia & Lymphoma Society (LLS) in the Fight Against Blood Cancer
RYE BROOK, NY, February 10, 2021 – The Leukemia & Lymphoma Society (LLS), the global leader in the fight against blood cancer, and Burlington Stores, the national retailer delivering amazing deals to customers every time they shop, teamed up for the 19th consecutive year to raise critical funds to support LLS’s goal of creating a world without blood cancer, and to further their LLS Children’s Init...
Patient organizations applaud strong actions to protect people with pre-existing conditions
WASHINGTON, D.C. – Thirty-three organizations representing millions of people with pre-existing conditions applaud the much-needed patient protections in two Executive Orders issued by President Biden on January 28. The organizations released the following statement: “President Biden’s actions this week represent a significant first step towards improving access to high-quality health coverage for people ...
NEW DRUG APPROVAL EXPANDS OPTIONS FOR PATIENTS WITH RARE MARGINAL ZONE LYMPHOMA AND ADVANCED FOLLICULAR LYMPHOMA
Rye Brook, N.Y. (February 5, 2021) – The U.S. Food and Drug Administration (FDA) today announced approval of UKONIQ™ (umbralisib), a once-daily, oral medication for the treatment of marginal zone lymphoma (MZL) that has returned or worsened following prior treatment with an anti-CD20 antibody. MZL is a clinical heterogeneous, slow-growing non-hodgkin lymphoma composed of three subtypes: extranodal, nodal or splen...
LLS Statement on Inauguration Day 2021
Our right to vote is the heart of our democracy, as is a free and fair election. The democratic process is critical to our work at The Leukemia & Lymphoma Society where civic engagement is a cornerstone of our values. Every day, LLS works directly with lawmakers at the state and federal levels to advance policies that serve the best interests of blood cancer patients. Every member of the LLS community – staff, ...
FDA Approval: Treatment Advance for Patients with Rare Blood Cell Disorder
Rye Brook, N.Y. (January 19, 2021) – On January 15, the U.S. Food and Drug Administration (FDA) announced approval of daratumumab plus hyaluronidase (Darzalex Faspro®) for adults with newly diagnosed light chain (AL) amyloidosis, a rare and serious blood cell disorder that may occur by itself or with myeloma. Daratumumab is used in combination with chemotherapy agents bortezomib (Velcade®) and cyclophosphamide (C...
FDA APPROVAL OF NEW CAR T-CELL THERAPY FURTHER SOLIDIFIES IMMUNOTHERAPY AS A MAINSTAY IN CANCER TREATMENT
Rye Brook, N.Y. (February 5, 2021) -- The U.S. Food and Drug Administration (FDA) today announced approval of a new CAR T-cell treatment for adult patients with certain forms of relapsed/refractory large B-cell lymphoma. With this latest approval, there are now four FDA-approved CAR T-cell therapies, and what was a brand-new approach introduced just three years ago, today is a mainstay in cancer care with scores...
The Leukemia & Lymphoma Society Applauds Bipartisan Agreement to Stop Surprise Medical Bills
Rye Brook, NY (December 21, 2020) - The Leukemia & Lymphoma Society issues the following statement in response to Congress including policies designed to protect patients from surprise medical bills in the stimulus bill scheduled for a vote Monday, Dec. 21, 2020: LLS applauds Congress for reaching a bipartisan agreement that will, after years of work, hold patients harmless from surprise medical bills. ...
FDA APPROVAL: TREATMENT ADVANCE FOR PATIENTS WITH MULTIPLE MYELOMA
Rye Brook, N.Y. (December 18, 2020) – The U.S. Food and Drug Administration (FDA) today announced approval of selinexor (Xpovio®) for adults with multiple myeloma who have had at least one prior type of treatment. Selinexor is used in combination with the chemotherapy drug bortezomib (Velcade®) and the corticosteroid dexamethasone in these patients. LLS supported development of selinexor with over $4 million i...